TARRYTOWN, N.Y., Feb. 9, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the fourth quarter and full year 2015 and provided an update on development programs.
Financial Highlights | ||||||||||||||||||||||
($ in millions, except per share data) | Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||
2015 | 2014* | % Change | 2015 | 2014* | % Change | |||||||||||||||||
EYLEA U.S. net product sales | $ | 746 | $ | 518 | 44 | % | $ | 2,676 | $ | 1,736 | 54 | % | ||||||||||
Total revenues | $ | 1,098 | $ | 802 | 37 | % | $ | 4,104 | $ | 2,820 | 46 | % | ||||||||||
Non-GAAP net income(2) | $ | 327 | $ | 328 | % | $ | 1,404 | $ | 1,175 | 19 | % | |||||||||||
Non-GAAP net income per share - diluted(2) | $ | 2.83 | $ | 2.79 | 1 | % | $ | 12.07 | $ | 10.00 | 21 | % | ||||||||||
GAAP net income | $ | 155 | $ | 90 | 72 | % | $ | 636 | $ | 338 | 88 | % | ||||||||||
GAAP net income per share - diluted | $ | 1.34 | $ | 0.78 | 72 | % | $ | 5.52 | $ | 2.98 | 85 | % | ||||||||||
* See note (4) below for an explanation of revisions made to certain amounts previously reported for the three months and year ended December 31, 2014. | ||||||||||||||||||||||
“Regeneron had a successful 2015, with strong growth in EYLEA sales for retinal diseases, the approval of Praluent for hypercholesterolemia, and important advances across all stages of our pipeline,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “In 2016, we look forward to driving increased physician education, patient access, and reimbursement for Praluent in the United States and to launching this important medicine in other countries around the world. We also anticipate significant pipeline progress including the U.S. FDA action on the sarilumab application for rheumatoid arthritis, the Phase 3 results and potential U.S. regulatory submission for dupilumab in atopic dermatitis, and the continued progress of our development programs for retinal diseases, asthma, pain, infectious diseases, and cancer. Realizing these important product and pipeline opportunities will require significant investments, which are essential to support our long-term growth and success.”
Business Highlights
EYLEA® (aflibercept) Injection for Intravitreal Injection
In the fourth quarter of 2015, net sales of EYLEA in the United States increased 44% to $746 million from $518 million in the fourth quarter of 2014. For the full year of 2015, net sales of EYLEA in the United States increased 54% to $2.676 billion from $1.736 billion for the full year 2014.
To read full press release, please click here.
